DE3876052D1 - Medizinische verwendung. - Google Patents
Medizinische verwendung.Info
- Publication number
- DE3876052D1 DE3876052D1 DE8888850306T DE3876052T DE3876052D1 DE 3876052 D1 DE3876052 D1 DE 3876052D1 DE 8888850306 T DE8888850306 T DE 8888850306T DE 3876052 T DE3876052 T DE 3876052T DE 3876052 D1 DE3876052 D1 DE 3876052D1
- Authority
- DE
- Germany
- Prior art keywords
- medical use
- igf
- insulin
- mammals
- mammalian
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 abstract 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000000578 peripheral nerve Anatomy 0.000 abstract 1
- 230000008929 regeneration Effects 0.000 abstract 1
- 238000011069 regeneration method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE8703625A SE8703625D0 (sv) | 1987-09-18 | 1987-09-18 | New medical use |
Publications (2)
Publication Number | Publication Date |
---|---|
DE3876052D1 true DE3876052D1 (de) | 1992-12-24 |
DE3876052T2 DE3876052T2 (de) | 1993-03-25 |
Family
ID=20369616
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE8888850306T Expired - Lifetime DE3876052T2 (de) | 1987-09-18 | 1988-09-16 | Medizinische verwendung. |
Country Status (7)
Country | Link |
---|---|
US (1) | US5068224A (de) |
EP (1) | EP0308386B1 (de) |
AT (1) | ATE82507T1 (de) |
DE (1) | DE3876052T2 (de) |
ES (1) | ES2043890T3 (de) |
GR (1) | GR3007092T3 (de) |
SE (1) | SE8703625D0 (de) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5166317A (en) * | 1988-10-31 | 1992-11-24 | Houston Biotechnology Incorporated | Neurotrophic factor |
US6440928B1 (en) | 1988-12-06 | 2002-08-27 | Colorado State University Research Foundation | Method for treating diabetic neuropathy with NGF |
US5093317A (en) * | 1989-06-05 | 1992-03-03 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factor |
US6723699B1 (en) | 1989-06-05 | 2004-04-20 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factors and analogs |
US5652214A (en) * | 1989-06-05 | 1997-07-29 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factors and analogs |
US6693076B1 (en) | 1989-06-05 | 2004-02-17 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factors and analogs |
ZA9010332B (en) * | 1989-12-22 | 1991-08-28 | Ciba Geigy | Method of reducing or preventing adverse effect of steroid therapy and compositions therefor |
US5679771A (en) * | 1990-02-13 | 1997-10-21 | Gropep Pty. Ltd. | Method for treating intestinal diseases |
AU637199B2 (en) * | 1990-02-13 | 1993-05-20 | Novozymes Biopharma Dk A/S | Method for treating intestinal diseases |
ATE165008T1 (de) * | 1990-02-13 | 1998-05-15 | Gropep Pty Ltd | Methode zur behandlung intestinaler krankheiten |
US5545719A (en) * | 1990-05-01 | 1996-08-13 | Neuromedica, Inc. | Nerve growth peptides |
SE9100099D0 (sv) * | 1991-01-11 | 1991-01-11 | Kabi Pharmacia Ab | Use of growth factor |
US5861373A (en) * | 1991-08-01 | 1999-01-19 | Genentech, Inc | IGF-1 to improve the neural condition |
DE69218948T2 (de) * | 1991-08-01 | 1997-07-31 | Auckland Uniservices Ltd | IGF-I zur Verbesserung der neuronale Lage |
US6310040B1 (en) * | 1991-11-08 | 2001-10-30 | Cephalon, Inc. | Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs |
WO1993010806A1 (en) * | 1991-11-25 | 1993-06-10 | Institute Of Molecular Biology, Inc. | Medicament for promoting growth of mammalian nerve |
IT1254706B (it) | 1991-12-23 | 1995-10-09 | Fidia Spa | Uso terapeutico del ganglioside gm1 nel trattamento del danno al midollo spinale |
SE9201573D0 (sv) * | 1992-05-19 | 1992-05-19 | Kabi Pharmacia Ab | Use of igf-1 |
US5420112A (en) * | 1992-06-12 | 1995-05-30 | Lewis; Michael E. | Prevention and treatment of peripheral neuropathy |
ES2140463T3 (es) * | 1992-06-12 | 2000-03-01 | Cephalon Inc | Prevencion y tratamiento de la neuropatia periferica. |
US20070078089A1 (en) * | 1992-07-06 | 2007-04-05 | Ishii Douglas N | Method for effecting changes in the central nervous system by administration of IGF-I or IGF-II |
SE9301667D0 (sv) * | 1993-05-14 | 1993-05-14 | Kabi Pharmacia Ab | New use |
JPH09509140A (ja) * | 1993-11-15 | 1997-09-16 | セルトリックス ファーマシューティカルズ,インコーポレイテッド | 神経学的障害の治療方法 |
SE9402370D0 (sv) | 1994-07-04 | 1994-07-04 | Pharmacia Ab | Use of IGF-I |
US5834029A (en) * | 1994-07-20 | 1998-11-10 | Cytotherapeutics, Inc. | Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment |
US5565428A (en) * | 1995-05-22 | 1996-10-15 | Genentech, Inc. | Method of administration of IGF-I |
US5741776A (en) * | 1995-05-22 | 1998-04-21 | Genentech, Inc. | Method of administration of IGF-I |
US6576636B2 (en) | 1996-05-22 | 2003-06-10 | Protarga, Inc. | Method of treating a liver disorder with fatty acid-antiviral agent conjugates |
US5795909A (en) | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
US6015786A (en) * | 1997-02-25 | 2000-01-18 | Celtrix Pharmaceuticals, Inc. | Method for increasing sex steroid levels using IGF or IGF/IGFBP-3 |
US6514937B1 (en) | 1997-02-25 | 2003-02-04 | Celtrix Pharmaceuticals, Inc. | Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3 |
US6025368A (en) * | 1997-02-25 | 2000-02-15 | Celtrix Pharmaceuticals, Inc. | Method for treating the symptoms of chronic stress-related disorders using IGF |
US5916569A (en) * | 1997-03-26 | 1999-06-29 | E. Martin Spencer | Human erectile dysfunction and methods of treatment |
US6121416A (en) | 1997-04-04 | 2000-09-19 | Genentech, Inc. | Insulin-like growth factor agonist molecules |
US6420518B1 (en) | 1997-04-04 | 2002-07-16 | Genetech, Inc. | Insulin-like growth factor agonist molecules |
US6225444B1 (en) | 1998-02-10 | 2001-05-01 | Protarga, Inc. | Neuroprotective peptides and uses thereof |
US7687039B2 (en) * | 1998-10-28 | 2010-03-30 | Covaris, Inc. | Methods and systems for modulating acoustic energy delivery |
PT1141014E (pt) * | 1999-01-06 | 2005-04-29 | Genentech Inc | Variante mutante do factor de crescimento semelhante a insulina (igf-i) |
GB0011278D0 (en) * | 2000-05-10 | 2000-06-28 | Univ London | Repair of nerve damage |
EP1282437B1 (de) | 2000-05-16 | 2008-03-19 | Genentech, Inc. | Behandlung von knorpelerkrankungen |
ATE463252T1 (de) * | 2000-08-29 | 2010-04-15 | Aurogen Inc | Methode zur behandlung des zentralnervensystems durch applikation von strukturanaloga von igf |
ATE439378T1 (de) * | 2001-02-09 | 2009-08-15 | Genentech Inc | Verfahren zur identifizierung von indirekten igf- 1-agonisten |
WO2002076402A2 (en) * | 2001-03-23 | 2002-10-03 | Protarga, Inc. | Fatty amine drug conjugates |
AU2002305099A1 (en) | 2001-03-23 | 2002-10-08 | Protarga, Inc. | Fatty alcohol drug conjugates |
US7714020B2 (en) * | 2001-05-24 | 2010-05-11 | Neuren Pharmaceuticals Limited | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate |
US7605177B2 (en) | 2001-05-24 | 2009-10-20 | Neuren Pharmaceuticals Limited | Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration |
EP1401808B1 (de) | 2001-05-24 | 2009-07-08 | Neuren Pharmaceuticals Limited | Gpe-analoga und peptidomimetika |
US20070004641A1 (en) * | 2001-05-24 | 2007-01-04 | Neuren Pharmaceuticals Limited | Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate |
GB0202906D0 (en) | 2002-02-07 | 2002-03-27 | Univ London | Prevention of myocardial damage |
JP3977162B2 (ja) * | 2002-06-21 | 2007-09-19 | 株式会社バンダイナムコゲームス | キャラクタ情報管理装置、プログラム及び情報記憶媒体 |
WO2004105749A1 (ja) * | 2003-05-27 | 2004-12-09 | Suntory Limited | 自律神経調節作用を有する組成物およびその使用方法 |
CN101022820A (zh) * | 2004-08-30 | 2007-08-22 | 特西卡股份有限公司 | 诊断和治疗胰岛素样生长因子缺陷疾病的方法和装置 |
JP2008533114A (ja) * | 2005-03-18 | 2008-08-21 | ユーシーエル ビジネス パブリック リミテッド カンパニー | メカノ成長因子ペプチドおよびその使用 |
AR059088A1 (es) * | 2006-01-20 | 2008-03-12 | Genzyme Corp | Administracion intraventricular de una proteina para esclerosis lateral amiotrofica |
CN103370074B (zh) * | 2011-01-26 | 2015-09-02 | 雪印惠乳业株式会社 | 感觉改善剂 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL71991A (en) * | 1983-06-06 | 1994-05-30 | Genentech Inc | Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes |
-
1987
- 1987-09-18 SE SE8703625A patent/SE8703625D0/xx unknown
-
1988
- 1988-09-16 ES ES88850306T patent/ES2043890T3/es not_active Expired - Lifetime
- 1988-09-16 DE DE8888850306T patent/DE3876052T2/de not_active Expired - Lifetime
- 1988-09-16 AT AT88850306T patent/ATE82507T1/de not_active IP Right Cessation
- 1988-09-16 EP EP88850306A patent/EP0308386B1/de not_active Expired - Lifetime
- 1988-09-16 US US07/245,146 patent/US5068224A/en not_active Expired - Lifetime
-
1993
- 1993-02-17 GR GR930400325T patent/GR3007092T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
DE3876052T2 (de) | 1993-03-25 |
EP0308386A1 (de) | 1989-03-22 |
EP0308386B1 (de) | 1992-11-19 |
SE8703625D0 (sv) | 1987-09-18 |
ATE82507T1 (de) | 1992-12-15 |
ES2043890T3 (es) | 1994-01-01 |
GR3007092T3 (de) | 1993-07-30 |
US5068224A (en) | 1991-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE82507T1 (de) | Medizinische verwendung. | |
FI875533A0 (fi) | Insulinpreparat foer non-parenteral dosering. | |
ATE204176T1 (de) | Verwendung von insulinähnlichen wachstumsfaktoren und analogen zur behandlung von erkrankungen der sehnerven | |
DE3873800D1 (de) | Zusammensetzungen zur behandlung von hypercholesterinaemie. | |
EP0363415A4 (en) | Compounds for the treatment of alzheimer's disease | |
AU2118488A (en) | Improvements in or relating to methods of treating damaged skin | |
DK106288D0 (da) | Osteoinduktive praeparater | |
ZA841597B (en) | Human nerve growth factor by recombinant technology | |
DE3855527D1 (de) | Doppelsträngige RNS zur Korrektur von Abnormalitäten von zirkulierenden Immunkomplexen und der Monozytenfunktion | |
DE69130497T2 (de) | Neue Verwendung von 1-Alpha-hydroxylierten-19-nor-vitamin-D-Verbindungen zur Behandlung von Psoriasis | |
ATE70715T1 (de) | Bindungsinduzierende komposition. | |
AU1553388A (en) | Treatment of diabetes | |
AU2158688A (en) | Use of bezafibrate for treating diabetes | |
AU7426487A (en) | Method of treating depression using d-fenfluramine | |
DE69110615D1 (de) | Verwendung von Aminosäuren zum Schutz von ischemischem Herzgewebe und dessen metabolischer Wiederherstellung. | |
ATE45675T1 (de) | Verwendung von interferon gamma (ifn-gamma) zur herstellung von praeparationen zur behandlung rheumatischer erkrankungen. | |
DE68916777D1 (de) | Verwendung von TNF zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis. | |
ATE130194T1 (de) | Subkutane verabreichung des humanen choriongonadotropins. | |
DE69218544D1 (de) | Verwendung von BMY 14802 zur Behandlung von Angstzuständen bei Patienten mit Benzodiazepin-Entzugserscheinungen | |
DE3877102D1 (de) | Methode fuer die behandlung von viraler gehirnentzuendung. | |
AU7931487A (en) | Therapeutic treatment of abnormal cell growth with follicle regulatory protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: CHIRON CORP., EMERYVILLE, CALIF., US |
|
8327 | Change in the person/name/address of the patent owner |
Owner name: NOVARTIS VACCINES AND DIAGNOSTICS,INC.(N.D.GES, US |